The most relevant information. Always.
As oncology care evolves, new genomic variants are constantly coming to light. The OncoExTra report has it covered. Because the test investigates the entire DNA coding sequence and the entire RNA transcriptome, reported results are continually updated to reflect the most up-to-date biomarkers.1
Download a sample report:
Clear and actionable insights personalize treatment guidance
For patients with advanced cancer, timely knowledge is crucial. The OncoExTra report highlights the most clinically relevant information first, to support prompt, point-of-care discussions between oncologists and their patients, leading to shared treatment decisions.1*
Discover mutations and fusions associated with FDA-approved treatments†
A snapshot of mutations and fusions delivers an ultra-comprehensive genomic picture, while providing information about treatment options
See tumor mutational burden and microsatellite instability
Immuno-oncology signatures (TMB/MSI) support truly personalized decisions
Find clinical trial options for your patient
Pairing your patients’ genomic results with potential clinical trials helps provide more treatment opportunities
Leverage immunohistochemistry results
For an additional level of genomic detail
*Select immunohistochemical (IHC) panels and single stains are offered as an optional add-on.
†The OncoExTra test is not an FDA-cleared or -approved IVD device or companion diagnostic for the referenced biomarkers and FDA-approved therapies.
ASCO® recommends fusion testing when:
there are FDA-approved fusion-targeted therapies for that specific disease, as well as testing for other fusions if no other variants are identified on panel-based DNA sequencing2
Actionable results within 14 days of sample submission receipt1
Results provided via our secure, intuitive online Precision Oncology provider portal
Expert report consultation at your convenience
Our medical team brings 20+ years of experience in genomic oncology—and is available to help with interpreting test results
MSI, microsatellite instability; TMB, tumor mutational burden.